Share：
Share this content in WeChat
X
[Chinese][PDF]80794
• Review •
Advances of diagnosis and treatment evaluation of intrahepatic cholangiocarcinoma in magnetic resonance imaging
ZHAO Li  ZHAO Xin-ming 

DOI:10.12015/issn.1674-8034.2017.10.013.


[Abstract] Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy following hepatocellular carcinoma (HCC). Incidence of ICC has increased in recent decades. ICC has a poor prognosis with a hidden onset and high degree malignancy. Magnetic resonance imaging (MRI) is increasingly applied in ICC because of its contribution to early diagnosis and treatment evaluation. This paper reviewed the progress of diagnosis and treatment evaluation of intrahepatic cholangiocarcinoma using magnetic resonance imaging.
[Keywords] Intrahepatic cholangiocarcinoma；Magnetic resonance imaging；Carcinoma, hepatocellular

ZHAO Li Department of Diagnostic, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

ZHAO Xin-ming* Department of Diagnostic, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

*Correspondence to: Zhao XM, E-mail: xinmingzh@sina.com

Conflicts of interest   None.

Received  2017-07-17
Accepted  2017-09-06
DOI: 10.12015/issn.1674-8034.2017.10.013
DOI:10.12015/issn.1674-8034.2017.10.013.

[1]
Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr, 2017, 6(1): 35-43.
[2]
Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and Meta-analysis. JAMA Surg, 2014, 149(6):565-574.
[3]
Xu J, Igarashi S, Sasaki M, et al. Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int, 2012, 32(7): 1156-1164.
[4]
Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr, 2017, 6(1): 22-34.
[5]
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol, 2014, 60(6): 1268-1289.
[6]
Konstantinidis IT, Arkadopoulos N, Ferrone CR. Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges. Chin Clin Oncol, 2016, 5(1): 9.
[7]
Chinchilla-Lopez P, Aguilar-Olivos NE, Garcia-Gomez J, et al. Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma. Ann Hepatol, 2017, 16(4): 565-568.
[8]
Choi SH, Lee SS, Kim SY, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology, 2017, 282(3): 771-781.
[9]
Wang K, Zhang H, Xia Y, et al. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr, 2017, 6(2): 79-90.
[10]
Bagante F, Spolverato G, Weiss M, et al. Assessment of the lymph node status in patients undergoing liver resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC staging system. J Gastrointest Surg, 2017, 23(4): 1-8.
[11]
Peporte AR, Sommer WH, Nikolaou K, et al. Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol, 2013, 82(3): e101-e106.
[12]
Kim R, Lee JM, Shin CI, et al. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol, 2016, 26(6):1808-1817.
[13]
Burra P, Bizzaro D, Ciccocioppo R, et al. Therapeutic application of stem cells in gastroenterology: an up-date. World J Gastroenterol, 2011, 17(34): 3870-3880.
[14]
Cardinale V, Semeraro R, Torrice A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol, 2010, 2(11): 407-416.
[15]
Jeong HT, Kim MJ, Chung YE, et al. Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol, 2013, 201(4):603-611.
[16]
Park HJ, Choi BI, Lee ES, et al. How to differentiate borderline hepatic nodules in hepatocarcinogenesis: emphasis on imaging diagnosis. Liver Cancer, 2017, 6(3): 189-203.
[17]
Suh CH, Kim KW, Kim GY, et al. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol, 2015, 25(4):950-960.
[18]
Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery, 2008, 143(3): 366-374.
[19]
Kajiyama K, Maeda T, Takenaka K, et al. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of 'scirrhous-type' and 'nonscirrhous-type' growth. Am J Surg Pathol, 1999, 23(8): 892-902.
[20]
Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology, 2006, 238(1): 150-155.
[21]
Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern: correlation with clinicopathologic findings. Radiology, 2011, 260(1): 148-157.
[22]
Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol, 2016, 26(2): 407-416.
[23]
Kang Y, Lee JM, Kim SH, et al. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology, 2012, 264(3): 751-760.
[24]
Lee J, Kim SH, Kang TW, et al. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology, 2016, 281(1): 119-128.
[25]
Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol, 2009, 20(9): 1589-1595.
[26]
Konstantinidis IT, Do R, Gultekin DH, et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol, 2014, 21(8): 2675-2683.
[27]
Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol, 2016, 61(13): 150-166.
[28]
Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY), 2017, 42(6): 1695-1704.
[29]
Zhou W, Zhang L, Wang K, et al. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging, 2017, 45(5): 1476-1484.

PREV Research advances in MEMRI for monitoring intracellular Ca2+ change at the early stage of MODS
NEXT Advances of quantitative dynamic contrast enhanced MRI in frequent neoplasms of uterus
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn